Dalbavancin for infective endocarditis: a single centre experience

References

• Bin Abdulhak AA, Baddour LM, Erwin PJ, Hoen B, Chu VH, Mensah GA, Tleyjeh IM. Global and regional burden of infective endocarditis, 1990-2010: a systematic review of the literature. Glob Heart. 2014;9(1):131–43.
   PubMedGoogle Scholar
• Murdoch DR, Corey RG, Hoen B, Mirò JM, Fowler VG, Jr, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the international collaboration on Endocarditis-prospective cohort study. Arch Intern Med. 2009;169(5):463–73.
   PubMedGoogle Scholar
• Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta J-P, Del Zotti F, Dulgheru R, El Khoury G, Erba PA, Iung B, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075–128.
   PubMed Web of Science ®Google Scholar
• Leone S, Ravasio V, Durante-Mangoni E, Crapis M, Carosi G, Scotton PG, Barzaghi N, Falcone M, Chinello P, Pasticci MB, et al. Epidemiology, characteristics, and outcome of infective endocarditis in Italy: the Italian study on endocarditis. Infection. 2012;40(5):527–35.
   PubMed Web of Science ®Google Scholar
• Pericàs JM, Llopis J, Muñoz P, Gálvez-Acebal J, Kestler M, Valerio M, Hernández-Meneses M, Goenaga MÁ, Cobo-Belaustegui M, Montejo M, et al. Contemporary picture of enterococcal endocarditis. J Am Coll Cardiol. 2020;75(5):482–94.
   PubMed Web of Science ®Google Scholar
• Pericà S JM, Llopis J, González-Ramallo V, Goenaga MÁ, Muñoz P, García-Leoni ME, Fariñas MC, Pajarón M, Ambrosioni J, Luque R, et al. Outpatient parenteral antibiotic treatment for infective endocarditis: a prospective cohort study from the GAMES cohort. Clin Infect Dis. 2019;69(10):1690–700.
   PubMed Web of Science ®Google Scholar
• Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT, Bruun NE, Høfsten DE, Fursted K, Christensen JJ, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380(5):415–24.
   PubMed Web of Science ®Google Scholar
• Dash RP, Babu RJ, Srinivas NR. Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic. Infect Dis. 2017;49(7):483–92.
   PubMed Web of Science ®Google Scholar
• Frantz S, Buerke M, Horstkotte D, Levenson B, Mellert F, Naber CK, Thalhammer F. Kommentar zu den 2015-Leitlinien der Europäischen Gesellschaft für Kardiologie zur Infektiösen Endokarditis. Kardiologe. 2016;10(3):142–8.
   Google Scholar
• Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, Vossen MG, Winkler S, Thalhammer F. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna. Clin Infect Dis. 2018;67(5):795–8.
   PubMed Web of Science ®Google Scholar
• Wunsch S, Krause R, Valentin T, Prattes J, Janata O, Lenger A, Bellmann-Weiler R, Weiss G, Zollner-Schwetz I. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections. Int J Infect Dis. 2019;81:210–4.
   PubMed Web of Science ®Google Scholar
• Bouza E, Valerio M, Soriano A, Morata L, Carus EG, Rodríguez-González C, Hidalgo-Tenorio MC, Plata A, Muñoz P, Vena A, et al. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018;51(4):571–7.
   PubMed Web of Science ®Google Scholar
• Hidalgo-Tenorio C, Vinuesa D, Plata A, Martin Dávila P, Iftimie S, Sequera S, Loeches B, Lopez-Cortés LE, Fariñas MC, Fernández-Roldan C, et al. DALBACEN cohort: Dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob. 2019;18(1):30..
   PubMed Web of Science ®Google Scholar
• Dinh A, Duran C, Pavese P, Khatchatourian L, Monnin B, Bleibtreu A, Denis E, Etienne C, Rouanes N, Mahieu R, et al. French national cohort of first use of dalbavancin: a high proportion of off-label use. Int J Antimicrob Agents. 2019;54(5):668–72.
   PubMed Web of Science ®Google Scholar
• Bryson-Cahn C, Beieler AM, Chan JD, Harrington RD, Dhanireddy S. Dalbavancin as secondary therapy for serious staphylococcus aureus infections in a vulnerable patient population. Open Forum Infect Dis. 2019;6(2):ofz028.
   PubMed Web of Science ®Google Scholar
• Dunne MW, Sahm D, Puttagunta S. Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies. Ann Clin Microbiol Antimicrob. 2015;14:19.
   PubMed Web of Science ®Google Scholar
• Knafl D, Tobudic S, Cheng SC, Bellamy DR, Thalhammer F. Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Eur J Clin Microbiol Infect Dis. 2017;36(4):677–80.
   PubMed Web of Science ®Google Scholar
• Spaziante M, Franchi C, Taliani G, D'Avolio A, Pietropaolo V, Biliotti E, Esvan R, Venditti M. Serum bactericidal activity levels monitor to guide intravenous dalbavancin chronic suppressive therapy of inoperable staphylococcal prosthetic valve endocarditis: a case report. Open Forum Infect Dis. 2019;6(11):ofz427.
   PubMed Web of Science ®Google Scholar
• Bork JT, Heil EL, Berry S, Lopes E, Davé R, Gilliam BL, Amoroso A. Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections. Infect Dis Ther. 2019;8(2):171–84.
   PubMed Web of Science ®Google Scholar
• Hakim A, Braun H, Thornton D, Strymish J. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: a case report. Int J Infect Dis. 2020;91:202–5.
   PubMed Web of Science ®Google Scholar